StreetAlpha
13F holdings · Q3 2026

Rosalind Advisors

Toronto, A6 · files as Rosalind Advisors, Inc.
Know the moment Rosalind Advisors filesYou follow Rosalind Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1622627

Rosalind Advisors reported 35 stocks worth $309M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DCTH (17.0%), VSTM (11.0%) and FENC (11.0%). Compared with Q2 2026, the fund opened new positions in REPL, TARA and RCKT, added to VSTM, AQST and MYO, trimmed XERS, VOR and PCVX and sold out of CLDX.

Latest filing: what Rosalind Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
7 new7 added9 trimmed1 sold outBought about $48.6M · sold about $28.8M
New 7
See all 7 →
Added 7
See all 7 →
Trimmed 9
  • Cybin Inc−$7M−29%
  • AVIR−$4.1M−74%
  • XERS−$3.1M−11%
  • PCVX−$2.9M−25%
  • TLPH−$1.2M−20%
See all 9 →
Sold out 1

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$309M+16.2% vs last quarter
Stocks held357 new · 1 sold out
Top 5 weight52.5%fairly concentrated
Turnover25%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
DCTH
Delcath Sys Inc
$52.7M17.0%3.3MNo change8 of 8
2
VSTM
Verastem Inc
$34.1M11.0%4.2M+250K (+6%)8 of 8
3
FENC
Fennec Pharmaceuticals Inc
$34M11.0%3.2MNo change8 of 8
4
XERS
Xeris Biopharma Holdings Inc
$24.7M8.0%2.6M−326K (−11%)8 of 8
5
CYBIN INC
$17.1M5.5%1.4M−569K (−29%)8 of 8
6
SVRA
Savara Inc
$16.4M5.3%3.2MNo change8 of 8
7
REPL
Replimune Group Inc
$13.2M4.3%1MNew position5 of 8
8
VOR
Vor Biopharma Inc Com New
$11.6M3.8%609K−39K (−6%)3 of 8
9
MDWD
Mediwound Ltd
$10.3M3.3%749KNo change8 of 8
10
XFOR
X4 Pharmaceuticals Inc
$9.3M3.0%3.2MNo change5 of 8
🔒 25 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CLDX
Celldex Therapeutics Inc
$7.4M200K

Options

valued at the underlying shares
StockTypeValueSharesChange
XNTK
Spdr Series Trust
Put$925K250K+109,400
SPY
Spdr S&P 500 ETF TR
Put$382K100K+100,000
VSTM
Verastem Inc
Call$357K294K+293,600
QQQ
Invesco Qqq TR
Put$258K50K+50,000
PEPG
Pepgen Inc
Call$257K413K+412,700

🔒 Free account: see all 11.

Reported value

last 8 quarters
$186MQ4 '24
$205MQ1 '25
$207MQ2 '25
$283MQ3 '25
$274MQ4 '25
$244MQ1 '26
$266MQ2 '26
$309MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Rosalind Advisors 13F FAQ

What does Rosalind Advisors own?

Rosalind Advisors reported 35 stocks worth $309M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DCTH (17.0%), VSTM (11.0%) and FENC (11.0%). The table above lists every position in the filing (the top 10 without an account).

What did Rosalind Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 7 new positions, 7 added to, 9 trimmed and 1 sold out. New positions include REPL, TARA and RCKT. It sold all of CLDX.

When will Rosalind Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Rosalind Advisors's portfolio worth?

The Q3 2026 filing reports $309M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.